Enforcement phase · no extension in force
CDSCO Revised Schedule M: compliance status in 2026
Short answer: Revised Schedule M (the GMP schedule of the Drugs Rules, 1945, notified by G.S.R. 922(E) on 28 December 2023)[1] now binds every drug manufacturing unit in India. Large manufacturers had to comply from 28 June 2024. Units with turnover below ₹250 crore that applied in Form A under G.S.R. 127(E) had until 31 December 2025[2]. From 1 January 2026 the rules apply to all units, and state drug controllers are inspecting against them under CDSCO’s letter of 7 November 2025[3][4].
Revised Schedule M: the inspection phase explained in 8 minutes
Darshan Singh walks through what regulators have reported since the MSME deadline passed and the 12 areas in the checklist below, with this dashboard on screen. The video is in Hindi, with English technical terms.
Video chapters
- 0:00The hook: what will the inspector write?
- 0:26Timeline: 28 Dec 2023 to 1 Jan 2026
- 1:17The DCGI letter of 7 Nov 2025
- 1:34From planning to enforcement
- 1:41On the ground: audits and Himachal Pradesh
- 2:27Industry estimate: about 26% of MSMEs
- 2:47NSQ samples and the Coldrif case
- 3:25What inspectors look at: the 12 areas
- 4:49Which gaps close fastest, and which do not
- 5:11What happens if a gap is found
- 5:38Missed the deadline: what to do
- 5:55Revised Schedule M versus WHO-GMP
- 6:10From 23 years of practice
- 7:28Three things to remember
- 8:01Next step
Every figure in the video comes from this page and its references, last verified 24 Oct 2026.
Revised Schedule M deadlines: who must comply, and from when
Three dates matter. Which one applies to a unit depends on its turnover and on whether it filed the Form A extension application in time.
| Category | Legal basis | Compliance date | Status, Oct 2026 |
|---|---|---|---|
| Large manufacturers, turnover above ₹250 crore | G.S.R. 922(E), 28 Dec 2023: six months from publication[1] | 28 Jun 2024 | In force |
| Units below ₹250 crore that filed Form A with an upgradation plan on ONDLS within three months (by 11 May 2025) | G.S.R. 127(E), 11 Feb 2025[2] | 31 Dec 2025 (binding from 1 Jan 2026) | Inspections under way |
| Units below ₹250 crore that did not file Form A | G.S.R. 922(E): twelve months from publication[1] | 28 Dec 2024 | Immediate inspection ordered 7 Nov 2025[3] |
| New manufacturing licences and new blocks, any size | Revised Schedule M as amended | Before licensing | Design stage |
Scroll sideways to see all columns.
Planning a new unit? Revised Schedule M sets the room-by-room area and layout baseline: see the Schedule M area requirements by dosage form and the plant setup cost calculator.
Revised Schedule M news and CDSCO updates, newest first
Notifications, enforcement letters, state inspection data and quality-alert figures. Each entry names its source. Filter by source type or search the log.
-
21 Aug 2026Data
July 2026 drug alert: 280 samples fail quality tests
CDSCO’s monthly alert for July 2026 listed 40 not-of-standard-quality (NSQ) samples from central laboratories and 240 from state laboratories, plus one spurious sample from Bihar. Monthly NSQ results drive CAPA notices and licence action on top of inspections.[7]
-
11 Apr 2026States
Himachal Pradesh: 270 units inspected, about 70 not operating
Himachal’s drug regulator had inspected 270 units since November 2025. About 70 of them were not operational, including units that surrendered licences, and 10 to 12 firms surrendered manufacturing licences in recent months. Only 116 of the state’s 655 drug manufacturing units had applied to upgrade.[8]
-
21 Mar 2026DoP
RPTUAS subsidy: WHO-GMP certificate now accepted at first instalment
The Department of Pharmaceuticals amended the Revamped Pharmaceuticals Technology Upgradation Assistance Scheme. An applicant can now claim the first instalment with either a Revised Schedule M certificate or a WHO-GMP certificate, and submits the other at the second instalment. Expenditure must still be incurred after 1 January 2024.[9]
-
23 Feb 2026CDSCO
DCGI: “If a unit cannot meet revised Schedule M, it should not be manufacturing drugs”
CDSCO said all audits are now benchmarked against Revised Schedule M with no extensions. About 1,250 sites had been audited since late 2022, about 1,100 of roughly 1,300 cough syrup makers had been physically audited, and around 850 CAPA notices were issued in ten months from NSQ surveillance. CDSCO also plans to use QCI-certified third-party agencies for some GMP audits; accreditation standards were still under discussion.[10]
-
1 Jan 2026CDSCO
Revised Schedule M binds every unit in India
The extended timeline under G.S.R. 127(E) ran only to 31 December 2025. From 1 January 2026 there is no category of manufacturer outside Revised Schedule M.[2]
-
29 Dec 2025MoHFW
Health ministry signals no further extension
Business Standard reported that the ministry was unlikely to extend the deadline. It had held a consultative meeting with high drug-manufacturing states, and an official was quoted saying “The ministry will not compromise on drug safety.” No extension notification followed.[11]
-
25 Dec 2025Industry
About one in four MSMEs had filed gap analyses
TeamLease RegTech estimated that about 1,700 of an estimated 6,500 non-GMP MSME units (26%) had submitted gap analyses or upgrade plans. Gujarat reported 639 of 647 units filed, Himachal about 116 of over 650. Estimates of the MSME base vary: the same report also cites about 8,500 MSMEs among roughly 10,500 units.[5]
-
17 Nov 2025CDSCO
67th DCC meeting: states told to prepare Revised Schedule M inspections
At the Drugs Consultative Committee, the DCGI asked state and UT licensing authorities to start preparing inspections under the 7 November letter. The committee also discussed para 14.15 (vendor approval), noting that robust vendor validation is essential before approving a raw-material supplier.[3]
-
7 Nov 2025CDSCO
CDSCO letter orders inspections and monthly reporting
The DCGI wrote to state and UT drug controllers: begin inspection and action immediately against units below ₹250 crore that did not apply for the extension, plan inspections of units that did, act against non-compliance under the Drugs and Cosmetics Act, and send monthly reports of observations and action taken.[3][4]
-
1 Oct 2025States
Coldrif: 364 GMP violations at the manufacturer
Tamil Nadu’s drugs control department recorded 39 critical and 325 major non-compliances at Sresan Pharma’s Kanchipuram plant. Coldrif batch SR-13 contained 48.6% w/v diethylene glycol, and more than 20 child deaths in Madhya Pradesh and Rajasthan were linked to the syrup. The case hardened the enforcement climate ahead of the deadline.[12]
-
11 May 2025CDSCO
Form A window closes
G.S.R. 127(E) allowed three months from publication to file Form A, with an upgradation plan, before the Central Licence Approving Authority. Units that missed it never received the extension.[2]
-
11 Feb 2025MoHFW
G.S.R. 127(E): conditional extension to 31 December 2025
Small and medium manufacturers with turnover below ₹250 crore could seek an extension to 31 December 2025 by filing Form A within three months, with a plan of upgradation and an undertaking that a gap analysis had been done.[2]
-
28 Dec 2024MoHFW
Original twelve-month deadline for small and medium units
Under G.S.R. 922(E), manufacturers below ₹250 crore turnover had twelve months from publication to comply. This remains the operative date for units that did not file Form A.[1]
-
28 Jun 2024MoHFW
Large manufacturers must comply
Manufacturers above ₹250 crore turnover had six months from publication of G.S.R. 922(E) to meet the revised schedule.[1]
-
11 Mar 2024DoP
RPTUAS revamped for Revised Schedule M upgrades
The Department of Pharmaceuticals widened its technology upgradation scheme to any manufacturing unit with turnover below ₹500 crore, MSMEs preferred, to support upgrades to Revised Schedule M and WHO-GMP standards.[13]
-
28 Dec 2023MoHFW
G.S.R. 922(E): Revised Schedule M notified
The Health Ministry amended the Drugs Rules, 1945 to replace Schedule M with revised good manufacturing practices and requirements of premises, plant and equipment for pharmaceutical products.[1]
No update matches that search. Try a broader word such as inspection or extension.
Revised Schedule M readiness checklist: 12 areas inspectors examine
Answer Yes, Partial or No for each area. The score is calculated in your browser and is not sent anywhere. It is indicative only: an inspection-grade gap analysis checks documents and the facility itself.
- Premises and HVACHVAC qualified, with documented pressure differentials, air changes and area classification for each dosage form
- Water systemPurified water (and WFI where needed) qualified, sanitised on schedule, with trended test data
- Pharmaceutical Quality SystemDocumented PQS with quality risk management (QRM) and product quality reviews (PQR)
- Equipment qualificationIQ, OQ and PQ complete and current for critical manufacturing and packing equipment
- Computerised systemsGMP software validated, with access control, audit trails and backups
- Data integrity (ALCOA+)Records attributable, legible, contemporaneous, original and accurate; no back-dating or shared logins
- Personnel and trainingJob-specific qualification records and a live training programme with competency checks
- QC laboratory and stabilityLab instruments qualified; stability studies running to approved protocols
- Vendor qualificationApproved vendor list backed by audits or questionnaires for API and key excipient suppliers
- Self-inspection and CAPAScheduled internal audits with documented findings and closed CAPA
- Complaints, recall and pharmacovigilanceWritten recall procedure tested by mock recall; complaints logged and trended; adverse-reaction reporting in place
- Documentation and Site Master FileCurrent SMF, controlled SOPs and batch records that match actual practice
Where units fail first: premises, HVAC and water systems need civil work and qualification time, so a gap there can stop production; documentation gaps can usually be closed in weeks. Plan capital against the first group. Background: HVAC qualification tests and validation under Schedule M.
Upgrade, buy or rent: routes to a Schedule M compliant unit
Where an existing building needs structural work, an upgrade can take longer than acquiring or leasing a facility that already meets the revised schedule. The right route depends on dosage forms, capital and the gaps found.
Upgrade your unit
Start with what the revised schedule requires, then cost it.
Key requirements of Revised Schedule MBuy a running plant
Running plants for sale across India. Check each listing’s licence and Schedule M status.
Browse pharma plants for saleCheck before you buy
Licence, GMP, utilities and liability checks for an acquisition.
50-point acquisition checklistManufacture on loan licence
Produce in a compliant host plant while your own unit is upgraded.
Loan licence consulting (Form 25A, 28A)Revised Schedule M FAQs for 2026
No. The only extension was G.S.R. 127(E), which ran to 31 December 2025 and covered only units below ₹250 crore turnover that filed Form A in time. No later notification extending it was found up to 24 October 2026, the ministry signalled in December 2025 that it would not extend, and in February 2026 CDSCO said all audits are benchmarked against Revised Schedule M with no extensions.
Action is taken under the Drugs and Cosmetics Act and Rules and is scaled to severity: inspection observations, show-cause notices, stop-production orders, and suspension or cancellation of the manufacturing licence. CDSCO’s November 2025 letter told states to act strictly and report monthly, so an uninspected unit cannot assume it will stay unnoticed. Licences suspended after NSQ findings are restored only after the root cause is fixed and the corrective action is shown to work.
It adds a Pharmaceutical Quality System with quality risk management and product quality reviews, and formal qualification and validation of equipment. It also adds controls on computerised systems, change control, complaint handling with pharmacovigilance, and written contracts for loan-licence and contract manufacture. In practice the heaviest spending usually goes on premises, HVAC and water-system qualification, while the PQS, data-integrity and documentation gaps take the most management time.
Commission a documented gap assessment now. It is the practical first step, and if an inspector arrives before the upgrades are finished, it is the strongest evidence that the unit is acting in good faith. Fix first the gaps that can stop manufacture (premises, HVAC, water), then prepare a costed, time-bound upgrade plan. Running with no assessment and no plan is the riskiest position a unit can be in.
No. Revised Schedule M compliance is a licensing condition for every manufacturer in India. A WHO-GMP certificate is a separate certificate, usually sought for export markets. The Department of Pharmaceuticals treats them as distinct documents: since March 2026 its RPTUAS subsidy accepts either one at the first instalment and asks for the other at the second.
Not formally. The revised schedule follows the structure of WHO GMP (PQS, QRM, PQR, qualification and validation), which brings Indian requirements much closer to international practice. But CDSCO is not a PIC/S participating authority (PIC/S member list checked 24 October 2026), so a Schedule M inspection does not carry PIC/S recognition. Export markets still apply their own inspections and certificates.
Sometimes. Where the existing building needs structural civil work, buying or leasing a facility that already meets Revised Schedule M can reach production sooner than a long upgrade. The answer depends on dosage forms, capital and the specific gaps, and an acquisition needs its own due diligence on licences, GMP status and liabilities before any money moves.
Close your Schedule M gaps before an inspector finds them
A facility-specific gap assessment, an upgrade roadmap and inspection preparation, from a practitioner with 23+ years in pharmaceutical QA, QC and regulatory affairs.
References
- [1]Lok Sabha. Unstarred Question No. 864: revised GMP for small pharmaceutical companies (reply citing G.S.R. 922(E) dated 28.12.2023 and its implementation timelines). New Delhi: Ministry of Chemicals and Fertilizers; 29 Nov 2024. Available from: eparlib.sansad.in. Accessed Oct 2026.
- [2]Ministry of Health and Family Welfare. G.S.R. 127(E): Drugs (Amendment) Rules, 2025, with Form A. Gazette of India, Extraordinary; 11 Feb 2025. Copy available from: medicaldialogues.in. Accessed Oct 2026.
- [3]Central Drugs Standard Control Organisation. Minutes of the 67th Drugs Consultative Committee meeting held on 17.11.2025. New Delhi: CDSCO; 2025. Available from: cdsco.gov.in. Accessed Oct 2026.
- [4]Press Trust of India. DCGI orders inspections of pharma units to ensure compliance with revised Schedule M norms. The Week; 10 Nov 2025. Available from: theweek.in. Accessed Oct 2026.
- [5]Business Standard. Just 1 in 4 MSME pharma units set for GMP transition as deadline nears. 25 Dec 2025. Available from: business-standard.com. Accessed Oct 2026.
- [6]Press Trust of India. Over 3,000 drug samples declared not of standard quality in 2024-25: Nadda (Lok Sabha reply). The Week; 12 Dec 2025. Available from: theweek.in. Accessed Oct 2026.
- [7]ETV Bharat. CDSCO flags 280 drug samples as NSQ or spurious in July. 21 Aug 2026. Available from: etvbharat.com. Accessed Oct 2026.
- [8]The Tribune. Small pharma units in Himachal shut shop as revised Schedule M norms tighten compliance net. 11 Apr 2026. Available from: tribuneindia.com. Accessed Oct 2026.
- [9]Department of Pharmaceuticals. Office Memorandum F.No. G-30015/25/2021-Scheme: modification in RPTUAS guidelines. New Delhi: Ministry of Chemicals and Fertilizers; 21 Mar 2026. Available from: pharma-dept.gov.in. Accessed Oct 2026.
- [10]Business Standard. CDSCO tightens quality net with audits, scientific cadre overhaul. 23 Feb 2026. Available from: business-standard.com. Accessed Oct 2026.
- [11]Business Standard. Health ministry unlikely to extend Schedule M GMP deadline for MSME pharma. 29 Dec 2025. Available from: business-standard.com. Accessed Oct 2026.
- [12]South First. Leaking equipment and non-pharma materials: inspection finds 364 violations at Kanchipuram Coldrif facility. Oct 2025. Available from: thesouthfirst.com. Accessed Oct 2026.
- [13]BioSpectrum India. Govt announces revamped pharmaceuticals technology upgradation assistance scheme. 11 Mar 2024. Available from: biospectrumindia.com. Accessed Oct 2026.
- [14]Pharmaceutical Inspection Co-operation Scheme. Members (participating authorities). Geneva: PIC/S. Available from: picscheme.org. Accessed 24 Oct 2026.
Disclaimer: this dashboard is technical and educational guidance, not legal or regulatory advice. Industry estimates are labelled as such and reflect the date of each report. Indian statutory instruments and CDSCO directions change; always confirm current requirements against the official Gazette, CDSCO and MoHFW notifications before making compliance or investment decisions. The PIC/S position in FAQ 6 is based on the PIC/S member list[14].